Common polymorphisms in the complement system and susceptiblity to bacterial meningitis

Journal of Infection

Volumn 66, Issue 3, 2013, Pages 255-262

  Adriani, Kirsten S ^a   Brouwer, Matthijs C ^a   Geldhoff, Madelijn ^a   Baas, Frank ^a   Zwinderman, Aeilko H ^a   Paul Morgan, B ^b   Harris, Claire L ^b   van der Ende, Arie ^a,c   Van de Beek, Diederik ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Bacterial meningitis; Common polymorphisms; Complement system; S. pneumoniae; SNPs

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ADULT; AGED; ARTICLE; BACTERIAL MENINGITIS; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; COHORT ANALYSIS; COMMUNITY ACQUIRED BACTERIAL MENINGITIS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL MENINGITIS; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CEREBROSPINAL FLUID; COMMUNITY-ACQUIRED INFECTIONS; COMPLEMENT C3; COMPLEMENT C5; COMPLEMENT SYSTEM PROTEINS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MENINGITIS, BACTERIAL; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84873267646     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.10.008     Document Type: Article

References (36)

1. Brouwer M.C., Tunkel A.R., van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010, 23:467-492.
2. van de Beek D., de Gans J., Tunkel A.R., Wijdicks E.F. Community-acquired bacterial meningitis in adults. N Engl J Med 2006, 354:44-53.
3. van de Beek D., de Gans J., Spanjaard L., Weisfelt M., Reitsma J.B., Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004, 351:1849-1859.
4. Hoogman M., van de Beek D., Weisfelt M., de Gans J., Schmand B. Cognitive outcome in adults after bacterial meningitis. J Neurol Neurosurg Psychiatry 2007, 78:1092-1096.
5. van de Beek D., Schmand B., de Gans J., Weisfelt M., Vaessen H., Dankert J., et al. Cognitive impairment in adults with good recovery after bacterial meningitis. J Infect Dis 2002, 186:1047-1052.
6. Weisfelt M., Hoogman M., van de Beek D., de Gans J., Dreschler W.A., Schmand B.A. Dexamethasone and long-term outcome in adults with bacterial meningitis. Ann Neurol 2006, 60:456-468.
7. Weisfelt M., van de Beek D., Spanjaard L., Reitsma J.B., de Gans J. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol 2006, 5:123-129.
8. Weisfelt M., de Gans J., van der Poll T., van de Beek D. Pneumococcal meningitis in adults: new approaches to management and prevention. Lancet Neurol 2006, 5:332-342.
9. van der Pol W.L., Huizinga T.W., Vidarsson G., van der Linden M.W., Jansen M.D., Keijsers V., et al. Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001, 184:1548-1555.
10. Heckenberg S.G., de Gans J., Brouwer M.C., Weisfelt M., Piet J.R., Spanjaard L., et al. Clinical features, outcome, and meningococcal genotype in 258 adults with meningococcal meningitis: a prospective cohort study. Medicine (Baltimore) 2008, 87:185-192.
11. Brouwer M.C., de Gans J., Heckenberg S.G., Zwinderman A.H., van der Poll T., van de Beek D. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:31-44.
12. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11:785-797.
13. Biesma D.H., Hannema A.J., van Velzen-Blad H., Mulder L., van Zwieten R., Kluijt I., et al. A family with complement factor D deficiency. J Clin Invest 2001, 108:233-240.
14. Fijen C.A., van den Bogaard R., Schipper M., Mannens M., Schlesinger M., Nordin F.G., et al. Properdin deficiency: molecular basis and disease association. Mol Immunol 1999, 36:863-867.
15. Jonsson G., Truedsson L., Sturfelt G., Oxelius V.A., Braconier J.H., Sjoholm A.G. Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine (Baltimore) 2005, 84:23-34.
16. Sprong T., Roos D., Weemaes C., Neeleman C., Geesing C.L., Mollnes T.E., et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 2006, 107:4865-4870.
17. Davila S., Wright V.J., Khor C.C., Sim K.S., Binder A., Breunis W.B., et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 2010, 42:772-776.
18. Brouwer M.C., Heckenberg S.G., de Gans J., Spanjaard L., Reitsma J.B., van de Beek D. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology 2010, 75:1533-1539.
19. Woehrl B., Brouwer M.C., Murr C., Heckenberg S.G., Baas F., Pfister H.W., et al. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest 2011, 121:3943-3953.
20. Maller J.B., Fagerness J.A., Reynolds R.C., Neale B.M., Daly M.J., Seddon J.M. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet 2007, 39:1200-1201.
21. Heurich M., Martinez-Barricarte R., Francis N.J., Roberts D.L., Rodríquez de Córdoba S., Morgan B.P., et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A 2011, 108:8761-8766.
22. Yates J.R., Sepp T., Matharu B.K., Khan J.C., Thurlby D.A., Shahid H., et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007, 357:553-561.
23. Bogaert D., Thompson C.M., Trzcinski K., Malley R., Lipsitch M. The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model. Vaccine 2010, 28:681-685.
24. Tuomanen E., Hengstler B., Zak O., Tomasz A. The role of complement in inflammation during experimental pneumococcal meningitis. Microb Pathog 1986, 1:15-32.
25. Rupprecht T.A., Angele B., Klein M., Heeseman J., Pfister H.W., Botto M., et al. Complement C1q and C3 are critical for the innate immune response to Streptococcus pneumoniae in the central nervous system. J Immunol 2007, 178:1861-1869.
26. Paul R., Obermaier B., Van Ziffle J., Angele B., Pfister H.W., Lowell C.A., et al. Myeloid Src kinases regulate phagocytosis and oxidative burst in pneumococcal meningitis by activating NADPH oxidase. J Leukoc Biol 2008, 84:1141-1150.
27. Jarva H., Jokiranta T.S., Wurzner R., Meri S. Complement resistance mechanisms of streptococci. Mol Immunol 2003, 40:95-107.
28. Paterson G.K., Mitchell T.J. Innate immunity and the pneumococcus. Microbiology 2006, 152:285-293.
29. Abeyta M., Hardy G.G., Yother J. Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun 2003, 71:218-225.
30. Kadioglu A., Weiser J.N., Paton J.C., Andrew P.W. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008, 6:288-301.
31. Li J., Glover D.T., Szalai A.J., Hollingshead S.K., Briles D.E. PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation. Infect Immun 2007, 75:5877-5885.
32. Despriet D.D., van Duijn C.M., Oostra B.A., Uitterlinden A.G., Hofman A., Wright A.F., et al. Complement component C3 and risk of age-related macular degeneration. Ophthalmology 2009, 116:474-480.
33. Park K.H., Fridley B.L., Ryu E., Tosakulwong N., Edwards A.O. Complement component 3 (C3) haplotypes and risk of advanced age-related macular degeneration. Invest Ophthalmol Vis Sci 2009, 50:3386-3393.
34. Spencer K.L., Olson L.M., Anderson B.M., Schnetz-Boutaud N., Scott W.K., Gallins P., et al. C3 R102G polymorphism increases risk of age-related macular degeneration. Hum Mol Genet 2008, 17:1821-1824.
35. Abrera-Abeleda M.A., Nishimura C., Frees K., Jones M., Maga T., Katz L.M., et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 2011, 22:1551-1559.
36. Haralambous E., Dolly S.O., Hibberd M.L., Litt D.J., Udalova I.A., O'dwyer C., et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 2006, 38:764-771.